BMY BM

BMY Bristol-Myers Squibb Company

Healthcare · Drug Manufacturers - General

7 · Fair Watch 16y streak

57.52

+3.85%

About the company

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers products for oncology, hematology, immunology, cardiovascular, and neuroscience indications. Its products include Opdivo for anti-cancer indications; Opdivo Qvantig, a subcutaneous PD-1 inhibitor for solid tumors; Orencia for active rheumatoid arthritis and psoriatic arthritis; Yervoy for the treatment of unresectable or metastatic melanoma; Reblozyl to treat anemia; Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Opdualag to treat unresectable or metastatic melanoma; and Camzyos for the treatment of symptomatic obstructive HCM. The company also offers Zeposia to treat relapsing forms of multiple sclerosis; Abecma for the treatment of patients with relapsed or refractory multiple myeloma; Sotyktu to treat moderate-to-severe plaque psoriasis; Krazati for the treatment of KRASG12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC); and Cobenfy to treat schizophrenia. In addition, it offers Eliquis for the reduction of risk of stroke/systemic embolism and for the treatment of DVT/PE; Revlimid, an oral immunomodulatory drug for multiple myeloma; Pomalyst/Imnovid for multiple myeloma; Sprycel for Philadelphia chromosome-positive chronic myeloid leukemia; and Abraxane to treat breast cancer. Further, the company provides Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC, as well as NSCLC and pancreatic cancer. It sells its products to wholesalers, distributors, specialty pharmacies, retailers, hospitals, clinics, and government agencies. The company has a strategic collaboration with Arcus Biosciences, Inc. to develop a treatment regimen that delivers tumor control in kidney cancer. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in Princeton, New Jersey.

4.38% 70.59% 2.52 16.11 3.57 53.80
52w 42.52 62.89

Dividend profile

Frequency Quarterly Growth (TTM) +2.5% CAGR 3y +4.7% +6.6% 16 years

Payment calendar

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec

Dividend history

14 15 16 17 18 19 20 21 22 23 24 25

Per-share dividend by year

Debt & leverage

230.97% 1.42 1.18 Total debt 46.4B USD Total cash 10.5B USD 19.0B USD

Latest reported balance-sheet figures.

Held by 10 investors · watched by 1

Sign up for an AI summary of this stock's dividend — and to track it in your portfolio.

Information, not financial advice.

The information on Quantic is provided for informational and educational purposes only. It is general in nature, does not take into account your personal financial situation, and does not constitute investment, financial, tax, or legal advice — nor a recommendation to buy or sell any security. Investing involves risk, including possible loss of principal; past performance is not a reliable indicator of future results. Market data comes from third-party providers and may be delayed or inaccurate. Before making any investment decision, consider your objectives, time horizon, risk tolerance, and diversification, and consult a qualified financial professional. Quantic is not a registered investment adviser or broker-dealer.

Quantic finance

Built with Elixir, Phoenix LiveView, and Tailwind CSS

© 2026 Francesc Leveque · Learn · Frequently Asked Questions